Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug vismodegib tested for Long-Term use in small study

NCT ID NCT00959647

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of the cancer drug vismodegib in 19 patients with ovarian cancer, basal cell carcinoma, or metastatic colorectal cancer. All participants had previously taken vismodegib in an earlier Genentech trial and were expected to benefit from continued treatment. The main goal was to track side effects and see how many patients stopped treatment due to them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vismodegib (also known as Erivedge)
What this could lead to
If successful, this study could show that long-term vismodegib treatment is safe and helps control certain cancers.
What could go wrong
This is a small, early-phase extension study with only 19 participants, so results may not apply broadly. Side effects are possible and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

19 people

The number who actually took part.

Started

Sep 2009

Finished

Jan 2014

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

This study only enrolled participants who took part in previous studies of vismodegib conducted by Genentech. Inclusion Criteria: * Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study or continued to receive vismodegib at the time the Genentech-sponsored parent study closed. * Expectation by the investigator that the participant may continue to benefit from additional vismodegib treatment. Exclusion Criteria: * Intervening anti-tumor therapy not specified in the parent study (ie, non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma colorectal cancer colorectal neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal cell carcinoma Metastatic colorectal cancer Ovarian cancer

Contacts and locations

Locations

  • Children's Hospital

    Oakland, California, 94609, United States

  • Comprehensive Cancer Care

    Palm Springs, California, 92262, United States

  • DermSurgery Associates, PA

    Houston, Texas, 77030, United States

  • Irfan Firdaus, D.O.

    Cincinnati, Ohio, 45242, United States

  • Johns Hopkins Univ Med Center

    Baltimore, Maryland, 21231, United States

  • Karmanos Cancer Institute..

    Detroit, Michigan, 48201, United States

  • Nevada Cancer Research Foundation

    Las Vegas, Nevada, 89169, United States

  • Stanford Univ Medical Center

    Stanford, California, 94305, United States

  • TGen Clinical Research Srvs

    Scottsdale, Arizona, 85258, United States

  • University Of Michigan

    Ann Arbor, Michigan, 48109-0934, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.